DBP International AB and N.N. Alexandrov National Cancer Center of Belarus has entered into a new agreement about the clinical use of Temodex
Background: On December 5, 2016 Double Bond Pharmaceutical International AB (publ) (“DBP”) announced a collaboration with the N. N. Alexandrov National Cancer Center in Belarus (“Alexandrov Cancer Center”). The main objective of this agreement was to gain access to the experience and resources relevant to the development of DBP's products such as SI-053, a drug to be used to treat brain tumors. In January 2017, the partnership agreement was further developed. It consisted of following up patients with brain tumors treated at that center and aimed to study several key parameters that